AZN: Summary for Astrazeneca PLC Common Stock - Yahoo Finance

UK Markets closed

AstraZeneca PLC (AZN)


NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
27.07-0.84 (-3.01%)
At close: 4:02PM EST
People also watch
GSKNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close27.91
Open27.39
Bid0.00 x
Ask0.00 x
Day's range26.86 - 27.42
52-week range25.55 - 35.04
Volume10,125,635
Avg. volume7,831,372
Market cap68.23B
Beta0.56
PE ratio (TTM)30.94
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield0.90 (3.32%)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • Reutersyesterday

    Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

    Bristol-Myers Squibb Co (BMY.N) shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's (MRK.N) leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.

  • Reuters - UK Focusyesterday

    Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

    Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck (Jakarta: 28586808.JK - news) & Co Inc's leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck (LSE: 0O14.L - news) shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.

  • Reuters - UK Focus2 days ago

    Bristol-Myers shares fall on lung cancer timeline setback

    Shares (Berlin: DI6.BE - news) of Bristol-Myers Squibb fell nearly 10 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co (Swiss: MRK-USD.SW - news) 's leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been jockeying for position in the battle to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck (LSE: 0O14.L - news) shares rose 3.8 percent to $62.60, while Bristol fell to $50.04.